Toggle Nav
Close
  • Menu
  • Setting

PIK-75 HCl

Catalog No.
A2080
Inhibitor of PI3K isoform p110α
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$61.00
In stock
10mg
$55.00
In stock
50mg
$143.00
In stock
100mg
$198.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

PIK-75 is a specific inhibitor of p110α isoform of PI3K with IC50 of 5.8 nM [1].

In acute myeloid leukemia cells, PIK-75 targeted the p110α isoform of PI3K, which led to a loss of connection between Bcl-xL and Bak. PIK-75 also transiently decreased Cdk7/9, leading to loss of Mcl-1 protein, and alleviation of its inhibition of pro-apoptotic Bak. The simultaneous loss of Bcl-xL and Mcl-1 led to rapid apoptosis. [2] In human monocyte-endothelial cell, PIK-75 suppressed the events of downstream signaling, including AKT phosphorylation, IKK activation, and NF-kB transcription. PIK-75 inhibited in vitro and in vivo production of TNF-α and IL-6, decreased the E-selectin, ICAM-1, and VCAM-1 expression, and blocked cell adhesion [3]. In human smooth muscle cells, PIK-75 decreased TNF-α-induced CD38 expression in asthmatic and nonasthmatic cells [4]. In pancreatic β-cells, acute treatment with PIK-75 enhanced the glucose-induced insulin secretion [5].

In vivo, PIK-75 significantly suppressed the histological abnormalities associated with dextran sulfate sodium-induced murine colitis. PIK-75 can attenuate experimental inflammation in the colon [3].

References:
[1]. Zheng Z, Amran SI, Thompson PE, Jennings IG. Isoform-selective inhibition of phosphoinositide 3-kinase: identification of a new region of nonconserved amino acids critical for p110α inhibition. Mol Pharmacol. 2011 Oct;80(4):657-64.
[2]. Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Récher C, Wei AH, Guthridge MA. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood. 2013 Aug 1;122(5):738-48.
[3]. Dagia NM, Agarwal G, Kamath DV, Chetrapal-Kunwar A, Gupte RD, Jadhav MG, Dadarkar SS, Trivedi J, Kulkarni-Almeida AA, Kharas F, Fonseca LC, Kumar S, Bhonde MR. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol Cell Physiol. 2010 Apr;298(4):C929-41.
[4]. Jude JA, Tirumurugaan KG, Kang BN, Panettieri RA, Walseth TF, Kannan MS. Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases. Am J Respir Cell Mol Biol. 2012 Oct;47(4):427-35.
[5]. Aoyagi K, Ohara-Imaizumi M, Nishiwaki C, Nakamichi Y, Ueki K, Kadowaki T, Nagamatsu S. Acute inhibition of PI3K-PDK1-Akt pathway potentiates insulin secretion through upregulation of newcomer granule fusions in pancreatic β-cells. PLoS One. 2012;7(10):e47381.

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt488.74
Cas No.372196-77-5
FormulaC16H14BrN5O4S·HCl
Solubilityinsoluble in H2O; insoluble in EtOH; ≥8.15 mg/mL in DMSO with gentle warming
Chemical NameN-[(E)-(6-bromoimidazo[1,2-a]pyridin-3-yl)methylideneamino]-N,2-dimethyl-5-nitrobenzenesulfonamide;hydrochloride
SDFDownload SDF
Canonical SMILESCC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)N(C)N=CC2=CN=C3N2C=C(C=C3)Br.Cl
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Biological Activity

Description PIK-75 is an inhibitor of P13K with IC50 values of 5.8 nM, 76 nM, 0.51 μM and 1.3 μM for p110α, p110γ, p110δ and p110β, respectively.
Targets p110α p110γ p110δ p110β DNA-PK  
IC50 5.8 nM 76 nM 0.51 μM 1.3 μM 2 nM  

Quality Control